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Mesenchymal stem cells (MSC) are a group of clonogenic
cells present among the bone marrow stroma and capable of
multilineage differentiation into mesoderm-type cells such as
osteoblasts, adipocytes and chondrocytes. Due to their ease of
isolation and their differentiation potential, MSC are being
introduced into clinical medicine in variety of applications and
through different ways of administration. Here, we discuss
approaches for isolation, characterization and directing differ-
entiation of human mesenchymal stem cells (hMSC). An
update of the current clinical use of the cells is also provided.
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Introduction
Human bone marrow-derived mesenchymal stem cells
(hMSC) (also known as skeletal stem cells, bone marrow
stromal cells or as recently suggested by the International
Society for Cytotherapy: multipotent mesenchymal stro-
mal cells1) are a group of clonogenic cells present among
the bone marrow stroma and capable of multilineage
differentiation into mesoderm-type cells such as osteo-
blast, adipocyte and chondrocyte2 and possibly, but still
controversial, other non-mesoderm type cells, for exam-
ple, neuronal cells or hepatocytes.3,4 Moreover, hMSC
provide supportive stroma for growth and differentia-
tion of hematopoeitic stem cells (HSC) and hemato-
poiesis.5
The identification and characterization of MSC has
been initiated through the pioneering work of Frieden-
stein in Russia6 and later Owen and co-workers in UK7
where culture systems for expanding the cells and for
studying their biological characteristics in vitro and in
vivo have been established. Recently, there has been an
increased interest in understanding the biology of MSC
due to their potential use for therapy of a variety of
diseases. The aim of this review is to provide an update
related to the biology of hMSC and the challenges facing
their use in therapy.
Isolation and characterization of hMSC
hMSC are fusiform, fibroblast-like cells. During their
initial growth in vitro, they form colonies (termed in
analogy with HSC: colony forming unit-fibroblasts
[CFU-f]).7–9 The cells are negative for hematpoietic
surface markers: CD34, CD45, CD14 and positive for a
variety of markers: Stro-1, CD29, CD 73, CD90, CD105,
CD166 and CD44.1,10,11 Differences exist among the
reported studies in the surface marker characteristics
that may be explained by variations in culture methods
and/or differentiation stage of the cells. However, a
number of surface markers has been suggested by a
working group within the International Society for
Cytotherapy as a minimal criteria for defining the cells
as MSC.1 Traditionally, hMSC have been isolated from
low-density mononuclear cell population of bone mar-
row, based on their selective adherence, compared to
hematopoietic cells, to plastic surfaces.8,9,12,13 One dis-
advantage of this method is the unavoidable hemato-
poietic cell contamination and the cellular heterogeneity
of cultures with respect of differentiation potential. The
concept of cellular ‘heterogeneity’ of MSC refers to
differences in the differentiation potential among single
cell clones of MSC. For example, in vitro single cell
cloning of hMSC has demonstrated that only around 30%
of the clonal MSC (that is, CFU-f) are multipotential and
thus true MSC.14 However, there are no current surface
markers that can be employed to isolate the multipotent
MSC prospectively.
During the recent years, several investigators have
tried different methods to enrich the cultures for the
multipotent MSC. One approach was to employ mono-
clonal antibodies in order to isolate a homogenous
population of cells with defined phenotype. One of the
first antibodies shown to enrich for hMSC is STRO-1
antibody, which identifies an as yet uncharacterized cell
surface epitope expressed by hMSC and erythrocytic
cells.15 An enrichment of hMSC has also been tried with
combining STRO-1 antibody with CD106 (VCAM-1) or
CD146 (MUC18), (STRO-1+/CD106+ or STRO-1+/
CD146+).16 Also, CD271 (low-affinity nerve growth
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factor receptor),17 CD18 (b2 integrin)18 or the embryonic
stem cell marker: SSEA-419 have been tried. While these
approaches are helpful in isolating MSC from hemato-
poietic cells, they do not distinguish multipotent MSC
from other cells present within the population of MSC
and no major differences have been reported between the
biological characteristics of the isolated cell populations
using these methods.
Due to the lack of specific ‘markers’ that define the
multipotent MSC, these cells are usually defined in
functional terms based on in vitro and in vivo functional
assays. MSC are capable for differentiation under
appropriate in vitro conditions, to mesoderm-type cells,
for example, osteoblasts, adipocytes and chondro-
cytes.10,20,21 In addition, ‘the gold standard’ assay for
MSC stemness is based on the ability of the cells to form
ectopic bone and bone marrow microenvironment
supporting hematopoesis upon implantation in an open
system (subcutaneous implantation) in immune deficient
severe combined immunodeficiency disease mice (Figure 1).
This assay has also been employed to demonstrate the
ability of the multipotenital MSC cells to exhibit self-
renewal and maintenance of ‘stemness’ capacity during
serial implantations.22
Other MSC-like populations
Other approaches have been employed and succeeded to
isolate cells from the bone marrow that share similarities
with MSC and possess additional interesting features.
One cell type that has received much attention is the
Multipotent Adult Progenitor Cell (MAPC), which has
been isolated from CD45/Glycoprotein A depleted
bone marrow-derived mononuclear cell fraction, through
selective adherence to laminin-coated plates under low
serum condition.23 The most interesting feature of MAPC
is their similarity to human embryonic stem cells with
respect to their extensive in vitro growth and pluripo-
tency.24 However, it has been difficult to reproduce these
results in other laboratories, since MAPC cannot be
isolated prospectively and they do not posses so far
specific surface markers for their identification. Side
population cells isolated from bone marrow based on
Hoechest dye exclusion has been isolated from mice and
demonstrated to be able to develop to MSC and also
hematopoietic stem cells and may thus represent a more
primitive stem cell population in the bone marrow.25
Recently, by using culture conditions resembling the
in vivo microenvironment of low oxygen tension, D’Ippolito
et al.26 have succeeded to isolate a population of MSC
named Marrow-Isolated Adult Multilineage Inducible cells.
These cells have been reported to have a better growth and
a wider differentiation potential compared to MSC cultured
by standard methods. While side-by-side comparison of
these different cell population is needed, in a preliminary
study no major differences could be detected between these
different cell populations.27
MSC with similar biological characteristics to those
derived from bone marrow, have been isolated from
other sources including peripheral blood,28 umbilical
cord blood,29 synovial membrane,30 deciduos teeth31 and
Figure 1 Histological analysis of heterotropic bone formation. (A) Histological analysis of heterotropic bone in either decalcified paraffin-
embedded implants (a, b and c) or non-decalcified plastic-embedded implants (d, e and f) harvested after 8 weeks of subcutaneous
transplantation of hMSC with HA/TCP in immunodeficient mice. The paraffin sections were stained with H&E, and plastic sections were
stained with Goldener’s Trichrome. Sections that demonstrating the regenerated bone (B), osteoid (O) and HA/TCP. Note that only the
Goldener’s Trichrome staining could distinguish between osteoid and mineralized bone. Sections show the advantage of using the in vivo
bone assay to compare the capacity of different hMSC clones to differentiate into bone in vivo. Sections were scored as, non-bone forming cells
(a and d), cells with moderate bone formation (b and e) and cells with high bone formation (c and f). (Magnification a–f  10). (B) Identifying
the origin of heterotropic formed bone in the implants by immunostaining using specific anti-human collagen type I, osteonectin and
osteopontin. Arrows show positive stained bone matrix and osteocytes. (Magnification a, b, c  20).
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recently amniotic fluid.32 These various MSC share some
common properties and surface phenotype but differ in
their differentiation potential and their gene expression
profile in a way that reflect their tissue of origin.33
From basic biology to clinical applications
The use of hMSC in clinical applications requires
understanding of their biological characteristics and
how to employ this information to isolate, expand
and differentiate the cells into a particular lineage
needed for therapy. Also, novel approaches to administer
the cells to the right place in the context of tissue repair
and regeneration need to be developed. In the following,
we will discuss four areas of translational research that
address these points and we will provide an update
regarding recent development.
Identification of a homogenous population of hMSC
with ‘stemness’ characteristics
There is a need for identification of surface markers that
can be employed prospectively to isolate a homogenous
population of multipotent hMSC or their progeny. As
seen above, hMSC exhibit a number of surface markers
that exhibit a high degree of sensitivity and thus can be
employed to obtain a cell population with MSC
characteristics. However, these markers lack specificity
and thus cannot distinguish between the multipotent
MSC and their differentiated progeny or other ‘mesench-
ymal’ cells. Our group has tried a global approach to
identify new surface markers for hMSC. We performed a
quantitative proteomic analysis of isolated membranes of
hMSC in undifferentiated and after short-term in vitro
differentiation using mass spectrometry.11 Using this
method, we have identified 463 unique proteins with
extremely high confidence, including typical markers of
hMSCs, for example, CD71, CD105, CD166, CD44, Thy1,
CD29 and CD63, among 148 integral membranes or
membrane-anchored proteins and 159 membrane-asso-
ciated proteins. A total of 29 integrins and cell adhesion
molecules, 20 receptors and 18 Ras-related small
GTPases were also identified. Upon differentiation of
hMSC to osteoblastic cells, the expression levels of 83
proteins increased by at least twofolds whereas the levels
of another 21 decreased by at least twofold.11 Future
studies are needed to validate these potential markers
and to employ them in the isolation of multipotent hMSC
or their progeny with specific phenotype.
Senescence and limited proliferative potential of hMSC
during long-term in vitro culture
The clinical use of hMSC requires the availability of a
large number of functionally competent cells with stable
phenotype. However, in vitro expansion of hMSC in
long-term culture of hMSC is limited. During long-term
in vitro culture of hMSC, the cells exhibit reduced
proliferation rate and finally enter a state of growth
arrest. This in vitro phenomenon is termed replicative
senescence.34–36 Replicative senescence is a general
phenomenon experienced by all normal somatic diploid
cells37 and it seems to apply for in vitro cultured adult
stem cells. Our group has studied extensively the in vitro
‘senescent phenotype’ of hMSC. First, we have demon-
strated that hMSC exhibit in vitro replicative senescence
during the current standard in vitro culture condi-
tions.21,34,36 Second, we found that maximal in vitro
population doubling (PD) of hMSC is dependent on the
age of the donor,21,36 hMSC derived from young donors
can be maintained in culture for around 40 PD while
hMSC strains derived from elderly donors can be grown
in cultures for only 24 PD. Interestingly, we did not
detect an donor age-related decrease in the number of
the initial clonal hMSC (that is, CFU-F) or in their
baseline differentiation potential.38
The phenomenon of in vitro replicative senescence is
caused by several factors including DNA damage,
accumulation of abnormal protein or mitochondrial
changes.37,39 However, progressive telomere shortening
during continuous in vitro growth as the result of absence
of telomerase activity in somatic cells, is emerging as a
fundamental mechanism.40,41 Similar to other adult stem
cells and in contrast with human embryonic stem cells,
we42 and others42,43 have demonstrated that cultured
hMSC lack telomerase activity because of absence of
human telomerase reverse transcriptase (hTERT) gene
expression which is the rate limiting factor for telomerase
activity in different types of somatic cells. In order to
overcome the in vitro senescent phenotype, we have
overexpressed hTERT in hMSC. This led to restoration of
the telomerase activity and elongation of telomere
lengths as well as extension of life span of hMSC.42 In
addition, the telomerized hMSC maintained MSC stem
cell characteristics in vitro and in vivo.10,42 Similar results
were obtained in studies that ‘telomerized’ smooth
muscle cells and endothelial cells.44,45
Telomerization of the cells is thus an attractive
approach for obtaining large number of cells for clinical
application.45 However, in our hMSC–TERT cells,
high telomerase activity led to genomic instability and
after around 250 PD to cell transformation.46 It is
important to note that this is not an inevitable outcome
of hTERT-overexpression. For example, some subpopu-
lations of our telomerized hMSC have been growing in
the laboratory for more than 3 years and still maintain
full differentiation potential and normal genetic
and epigenetic profiles.46,47 However, from a clinical
application point of view, isolation of hMSC with
naturally regulated telomerase activity may provide a
safer cell type for tissue engineering applications. As
mentioned before, some of the isolated hMSC popula-
tions seem to express endogenous telomerase activity at
least at the culture initiation and at a low levels.16,26
Alternatively, transient induction of hTERT is another
alternative approach. We have recently demonstrated
that the lack of telomerase activity in hMSC is due to an
epigenetic mechanism and that hTERT expression can be
restored transiently by treating the cells with trichostatin
A.48 Thus, it may be possible to identify ways for
telomerization of the cells using small chemical mole-
cules. The possibility of obtaining a large number of
these cells with maintained genomic stability during
long-term culture with these approaches remains to be
determined.
Finally, it should be mentioned that other approaches
to improve in vitro expansion and to extend the in vitro
life span of hMSC have been reported. Among these
treatment of the hMSC with growth factors, for example,
FGF249,50 or culturing the cells under low oxygen
tension51 or in 3D environment.52 These physiological
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approaches may be useful ways for obtaining large
number of cells for clinical applications.
Control of differentiation of hMSC
The multi-potential differentiation capacity of MSC, for
example, into bone, cartilage, is the basis for their use in
therapy. It is generally accepted that before introducing
the cells into patients, they need to be differentiated into
a specific lineage since there is a concern that clinical use
of undifferentiated stem cells may lead to a situation of
uncontrolled proliferation and differentiation resulting in
serious complications including tumor formation. How-
ever, this hypothesis requires further testing and exam-
ination Nevertheless, it is necessary to develop protocols
that limit the differentiation potential of hMSC into a
particular lineage before their use in therapy. Generally,
two approaches have been suggested in the literature to
achieve this goal. A genetic approach, where lineage-
specific transcription factors have been overexpressed in
order to induce lineage-specific MSC differentiation. For
examples, for osteoblast differentiation, core-binding
factor 1/Runx2,53 ostrix54 and lipoprotein-related recep-
tor 5 and its downstream effectors among Wnt signaling
molecule55 can be employed. Peroxisome proliferator-
activated receptor-g 2 (PPARg2)56 and Sox957 can be
employed to induce adipocyte or chondrocyte lineage,
respectively. The genetic approach provides important
information regarding the biological control of differ-
entiation of hMSC but may not be applicable for
generating cells suitable for therapy. Alternatively, a
‘micro-environmental’ approach can be employed since
MSC lineage-specific differentiation depends on the
microenvironmental signals received by the cells (the
so-called stem cell niche). In this approach, MSC are
exposed to different mixtures of growth factors, hor-
mones and extra-cellular matrix components to induce
their differentiation. For osteoblast differentiation,
several factors have been employed to enhance diff-
erentiation, for example, BMPs,58 Wnt59 or to inhibit
differentiation, for example, Dlk1/Pref-160 Noggin.61
In order to identify the intracellular signaling path-
ways that determine the differentiation fate of MSC, we
have recently employed a global quantitative proteomic
approach to identify phosphotyrosine signaling mole-
cules that are important for MSC differentiation into
osteoblasts.62 We have employed a newly developed
quantitative proteomic method called stable isotope
labeling in cell culture to compare the signaling pathway
initiated by epidermal growth factor (EGF) and that
resulted in osteoblast differentiation with that of platelet-
derived growth factor (PDGF) that did not. Interestingly,
more than 90% of the signaling proteins were utilized by
EGF and PDGF, while the phosphatidylinositol 3-kinase
pathway was exclusively activated by PDGF implicating
it as a possible control point. Indeed, chemical inhibition
of PI3K in PDGF-stimulated cells rescued the osteoblast
differentiation phenotype62 (Figure 2). These studies
demonstrate the ability of state-of-the-art quantitative
proteomic approaches to identify targets for pharmaco-
logical intervention in order to control MSC differen-
tiation.
Systemic delivery of MSC
Systemic transplantation of MSC in protocols similar to
those utilized in hematpoietic stem cell transplantation
can provide an attractive and clinically relevant method
for delivering cells for therapy. However, the challenge is
how to improve the engraftment efficiency of MSC to
bone marrow and bone63,64 to allow for biologically
relevant effects. MSC can be detected in peripheral blood
in different species despite in very low number.28 The
physiological role of the circulating MSC is not known
but their presence suggests that that they can home to
target tissues and may thus participate in tissue turnover.
We have demonstrated that hMSC exhibit a poor ability
to cross-capillary barriers when transplanted systemi-
cally to non-injured tissues and the majority of cells get
entrapped in lung capillaries when administered intra-
venously.64 In a recent study,65 body irradiation has been
demonstrated to increase the percentage of cells homing
to different organs. Thus, there is a need for further
studies to understand and enhance the mechanisms
leading to transcapillary migration of MSC and their
homing to a specific organ.
Current applications of MSC in therapy
Four areas for potential clinical use of MSC have been
explored: local implantation of MSC for localized
diseases, systemic transplantation, combining stem cell
therapy with gene therapy and use of MSC in tissue
engineering protocols.
Local implantation of MSC
Several animal studies have demonstrated the efficacy of
using MSC in treatment of bone defects.66,67 Some clinical
case reports have demonstrated the success of locally
injected ex vivo expanded autologus MSC for treatment
Figure 2 Quantitative signaling proteomic study of osteoblast
differentiation using stable isotope labeling by amino acids in cell
culture method (SILAC). A quantitative proteomic strategy that
metabolically labels the entire proteome, making it distinguishable
by MS analysis (SILAC) was used to map the proteomic signaling
network initiated by epidermal growth factor (EGF) versus platelet-
derived growth factor (PDGF) in hMSC. This quantitative method
enable identifying phosphatidylinositol 3-kinase (PI3K) pathway as
one of the key regulatory pathway of osteoblast differentiation,
where inhibition of PI3K by Wortmannin in PDGF-treated cells
leads to enhance osteoblast differentiation and in vivo bone
formation.
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of large bone defects in patients with defective fracture
healing.68 Also, repair of cartilage defects has been
tried.69 Recently, the use of MSC or subset of the cells
with vascular endothelial phenotype or a mixture of HSC
and MSC stem cell progenitors have been tried in a small
number of patients with vascular ischemia secondary to
peripheral arterial disease,70 coronary artery disease71,72
or non-healed chronic skin wounds.73 The injected cells
were well tolerated and some spectacular results were
obtained in some of these trails. However, these initial
encouraging results need to be confirmed in randomized
clinical trials with adequate number of patients.
Systemic transplantation of MSC
Systemic MSC transplantation has been tried in specific
diseases and the results were generally encouraging.
Systemic transplantation of allogenic normal bone
marrow or purified allogenic MSC has been tried in
children with severe osteogensis imperfecta.74–76 In these
studies, engraftment of donor MSC in bone and their
ability to differentiate into active osteoblasts has been
demonstrated. Also, an increase in the body length and
total bone mineral density in the treated children
have been demonstrated.74–76 However, these studies
have some limitation especially the number of MSC
homed to bone in these patients was small, the patients
received other concurrent therapies and the studies did
not enroll a control group. Thus, the real contribution of
the transplanted MSC to the observed positive clinical
response is difficult to determine. Another recent
approach for cell therapy of osteogensis imperfecta was
performed by in utero transplantation of allogenic fetal
MSC into a female fetus with multiple intrauterine
fractures at the 32nd week of gestation.77 Interestingly,
engraftment of donor cells and increased bone miner-
alization have been observed in the bone of the patient at
9 months of age.77 Case reports of well tolerated
allogenic MSC transplantation and some clinical im-
provement have been reported in patients with Hurler’s
syndrome and severe idiopathic aplastic anemia.78,79
Furthermore, combining MSC transplantation with
HSC transplantation was tried to increase the homing
ability of HSC to bone marrow.80 Also, a promising area
of clinical application is the use of systemic transplanta-
tion of MSC in treatment of graft-versus-host-disease
during allogenic HSC transplantation.81,82 The rationale
behind the use of MSC in this context is the increasing
evidence that MSC exerts immune-regulatory effects.81,82
Finally, the field of systemic MSC transplantation is
encouraged by the fact that MSC are hypoimmunogenic
and thus allowing MSC transplantation between HLA-
incompatible individuals.83
Combining stem cell therapy with gene therapy
The use of gene-modified stem cells in the context of
gene therapy is an attractive option due to theoretical
advantage of stem cells compared to somatic cells with
respect to higher proliferative capacity and long-term
survival. Genetically modified MSC can deliver genes or
proteins into organs or tissues with specific need for gene
therapy. Some these approaches have been tried in
animal models. MSC cells expressing ectopic BMP-2
have been used successfully for repair of articular
cartilage and for bone regeneration in animal models.84,85
In a model for hemophilia treatment, hMSC transduced
with a retroviral vector encoding a human B-domain
deleted FVIII (hFVIIIdeltaB) cDNA exhibited long-term
engraftment, in absence of myeloablative conditioning as
well as persistent expression of the therapeutic levels of
FVIII in the plasma of recipient mice.86 Moreover, MSC
have been demonstrated to be able to express exogenous
proteins (for example, IL-3) for extended period of time
and to maintain this ability after transplantation
in vitro.87 Therapy based on these genetic modified cells
is thus possible.
Tissue engineering
Tissue engineering may provide alternative ways for
obtaining tissues and organs needed for transplantation
due to lack of sufficient number of organ donors and
limitations attributable to immunological rejection
and mismatch of physical dimensions. Tissue engineer-
ing may allow obtaining patients own cells, seeding
them on biodegradable scaffolds that allow formation of
a particular tissue.88 These tissues can be used to repair
tissue defects due to disease or trauma. Also, tissue
engineering may also allow ex vivo engineering of tissue
by the means of 3D bio-scaffolds seeded with mature cell
or stem cells and cultivated in bioreactors that lead to the
formation of tissues or organs, for example, liver, hearts,
cartilage or kidneys.88 MSC are candidates for use in
tissue engineering protocols because of the relative ease
for establishing the cells in vitro and their differentiation
potential.89 Several scaffolds are currently available and
may be classified as either: (a) biologically derived
polymers isolated from extracellular matrix, plants and
seaweed, for example, collagen type I or fibronectin,
alginate from brown algae or (b) synthetic, for example,
hydroxyapatite, tricalcium phosphate ceramics, polylac-
tide and polyglycolide and a combination of these in the
form of poly DL-lactic-co-glycolic acid.88,89 There exists
several animal experiments showing the success of using
this approach, for example, for treatment of large bone
defects in animal models90 and for use in tissue
reconstruction.91 It is expected that transplantation of
tissues based on these methods to humans will be
achieved in the coming years.
Conclusion
Studying the biology of MSC and introducing these cells
into the clinic through cell-based therapy protocols is a
very exciting area of basic and clinical experimental
research. It is expected that MSC with their interesting
biological characteristics will provide new approaches to
treatment of chronic diseases. In addition, studying their
biology will provide insight into basic biological pro-
cesses of control of cell proliferation, differentiation and
tissue turnover. It is hoped that this information will
benefit the whole field of regenerative medicine.
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